Age (odds ratio: 0.845; 95% confidence interval, 0.753–0.948; p = 0.004), RDI (odds ratio: 1.071; 95% confidence interval, 1.023–1.121; p = 0.003), and baseline ANG-2 levels (odds ratio: 0.996; 95% confidence interval, 0.993–0.999; p = 0.002) were significantly associated with OR in patients with unresectable HCC who were treated with lenvatinib (Table 2). Here, ANGPT2 is linked to hepatocellular carcinoma.